CN101023177A - 非-整合型以及非-复制型慢病毒,制剂及其应用 - Google Patents
非-整合型以及非-复制型慢病毒,制剂及其应用 Download PDFInfo
- Publication number
- CN101023177A CN101023177A CNA2005800209389A CN200580020938A CN101023177A CN 101023177 A CN101023177 A CN 101023177A CN A2005800209389 A CNA2005800209389 A CN A2005800209389A CN 200580020938 A CN200580020938 A CN 200580020938A CN 101023177 A CN101023177 A CN 101023177A
- Authority
- CN
- China
- Prior art keywords
- sequence
- slow virus
- cell
- virus
- promotor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16061—Methods of inactivation or attenuation
- C12N2740/16062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
- C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
Description
Claims (24)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0407017A FR2872170B1 (fr) | 2004-06-25 | 2004-06-25 | Lentivirus non interactif et non replicatif, preparation et utilisations |
FR0407017 | 2004-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101023177A true CN101023177A (zh) | 2007-08-22 |
Family
ID=34948183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2005800209389A Pending CN101023177A (zh) | 2004-06-25 | 2005-06-24 | 非-整合型以及非-复制型慢病毒,制剂及其应用 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8119119B2 (zh) |
EP (1) | EP1761635B1 (zh) |
JP (1) | JP4861314B2 (zh) |
CN (1) | CN101023177A (zh) |
AT (1) | ATE524554T1 (zh) |
AU (1) | AU2005266221B2 (zh) |
CA (1) | CA2579753C (zh) |
FR (1) | FR2872170B1 (zh) |
IL (1) | IL179740A0 (zh) |
WO (1) | WO2006010834A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214938A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 特异促进 bace1 基因高表达的慢病毒表达载体及应用 |
WO2021212279A1 (zh) * | 2020-04-20 | 2021-10-28 | 广东东阳光药业有限公司 | 慢病毒的滴度提高型转移质粒 |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
WO2007091066A1 (en) * | 2006-02-07 | 2007-08-16 | Ucl Business Plc | Applications of non-integrating lentiviral vectors |
PL2020444T3 (pl) * | 2007-08-03 | 2017-10-31 | Pasteur Institut | Wadliwe nieintegrujące lentiwirusowe wektory przenoszące dla szczepionek |
EP2185192B1 (en) | 2007-08-03 | 2018-10-31 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
AU2013203404B2 (en) * | 2007-08-03 | 2016-10-13 | Centre National De La Recherche Scientifique (Cnrs) | Lentiviral gene transfer vectors and their medicinal applications |
CA2703045C (en) | 2007-10-25 | 2017-02-14 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
AU2009228183A1 (en) * | 2008-03-28 | 2009-10-01 | Virxsys Corporation | Lentivirus-based immunogenic vectors |
WO2009131706A1 (en) * | 2008-04-26 | 2009-10-29 | Yung-Nien Chang | Site-specific-integration lentiviral vectors |
EP2405945A4 (en) * | 2009-03-13 | 2012-09-12 | Lentigen Corp | NON-INTEGRAL RETROVIRAL VECTOR VACCINES |
WO2010117464A1 (en) | 2009-04-09 | 2010-10-14 | Sangamo Biosciences, Inc. | Targeted integration into stem cells |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
EP2385107B1 (en) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Lentiviral vector based immunological compounds against malaria |
WO2012152912A1 (en) | 2011-05-12 | 2012-11-15 | Newvectys | Genetically modified pig as a cancer prone model |
ES2651922T3 (es) | 2011-11-08 | 2018-01-30 | Institut Pasteur | Polipéptidos de afinidad elevada para MAST2 y usos de los mismos |
GB201202516D0 (en) | 2012-02-13 | 2012-03-28 | Ucl Business Plc | Materials and methods relating to packaging cell lines |
PT2831095T (pt) | 2012-03-30 | 2019-01-30 | Immune Design Corp | Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign |
US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
SG10201707569YA (en) | 2012-12-12 | 2017-10-30 | Broad Inst Inc | Delivery, Engineering and Optimization of Systems, Methods and Compositions for Sequence Manipulation and Therapeutic Applications |
EP3434776A1 (en) | 2012-12-12 | 2019-01-30 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
CN111643663A (zh) | 2013-03-15 | 2020-09-11 | 细胞基因公司 | 修饰的t淋巴细胞 |
BR112015031608A2 (pt) | 2013-06-17 | 2017-08-22 | Massachusetts Inst Technology | Aplicação e uso dos sistemas crispr-cas, vetores e composições para direcionamento e terapia hepáticos |
KR20160034901A (ko) | 2013-06-17 | 2016-03-30 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작에 최적화된 crispr-cas 이중 닉카아제 시스템, 방법 및 조성물 |
AU2014281026B2 (en) | 2013-06-17 | 2020-05-28 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
WO2014204727A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof |
EP3011032B1 (en) * | 2013-06-17 | 2019-10-16 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
RU2716421C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка, применение и применения в терапии систем crispr-cas и композиций для целенаправленного воздействия на нарушения и заболевания с использованием вирусных компонентов |
WO2015040063A1 (en) * | 2013-09-17 | 2015-03-26 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Lentiviral vectors having a mutated integrase protein and uses thereof |
EP2878667A1 (en) | 2013-11-29 | 2015-06-03 | Institut Pasteur | TAL effector means useful for partial or full deletion of DNA tandem repeats |
BR112016013201B1 (pt) | 2013-12-12 | 2023-01-31 | The Broad Institute, Inc. | Uso de uma composição compreendendo um sistema crispr-cas no tratamento de uma doença genética ocular |
SG10201804974RA (en) | 2013-12-12 | 2018-07-30 | Broad Inst Inc | Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders |
WO2015089364A1 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Crystal structure of a crispr-cas system, and uses thereof |
EP3080271B1 (en) | 2013-12-12 | 2020-02-12 | The Broad Institute, Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
GB201322798D0 (en) | 2013-12-20 | 2014-02-05 | Oxford Biomedica Ltd | Production system |
CN110938655A (zh) | 2014-04-25 | 2020-03-31 | 蓝鸟生物公司 | Mnd启动子嵌合抗原受体 |
ES2846811T3 (es) | 2014-06-06 | 2021-07-29 | Bluebird Bio Inc | Composiciones de células T mejoradas |
EP3031923A1 (en) * | 2014-12-11 | 2016-06-15 | Institut Pasteur | Lentiviral vector-based japanese encephalitis immunogenic composition |
EP3230321B1 (en) | 2014-12-12 | 2019-08-28 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
EP3985115A1 (en) | 2014-12-12 | 2022-04-20 | The Broad Institute, Inc. | Protected guide rnas (pgrnas) |
WO2016205759A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation |
CA2989830A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute, Inc. | Crispr enzyme mutations reducing off-target effects |
WO2017053707A1 (en) | 2015-09-23 | 2017-03-30 | Sensoriant, Inc. | Method and system for using device states and user preferences to create user-friendly environments |
WO2017060662A1 (en) * | 2015-10-07 | 2017-04-13 | The Secretary Of State For Health | Method for providing a control for use in a screen for pathogenic virus |
US11479755B2 (en) | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
JP7125351B2 (ja) | 2016-04-14 | 2022-08-24 | 2セブンティ バイオ インコーポレイテッド | サルベージキメラ抗原受容体システム |
MA45996A (fr) | 2016-08-16 | 2021-06-02 | Bluebird Bio Inc | Variants d'endonucléase de homing du récepteur alpha de l'il-10, compositions et méthodes d'utilisation associées |
MA46059A (fr) | 2016-08-23 | 2019-07-03 | Bluebird Bio Inc | Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation |
IL265045B2 (en) | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
MA46543A (fr) | 2016-10-17 | 2019-08-21 | Bluebird Bio Inc | Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation |
WO2018094244A1 (en) | 2016-11-17 | 2018-05-24 | Bluebird Bio, Inc. | TGFβ SIGNAL CONVERTOR |
MA47847A (fr) * | 2016-12-06 | 2020-01-29 | Bluebird Bio Inc | Thérapie génique pour traiter la mucopolysaccharidose de type i |
AU2017370673A1 (en) * | 2016-12-06 | 2019-06-27 | Bluebird Bio, Inc. | Gene therapy for mucopolysaccharidosis, type II |
EP3357504A1 (en) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Functional screening of antigenic polypeptides - use for the identification of antigens eliciting a protective immune response and for the selection of antigens with optimal protective activity |
EP3357506A1 (en) | 2017-02-02 | 2018-08-08 | Institut Pasteur | Multiple malaria pre-erythrocytic antigens and their use in the elicitation of a protective immune response in a host |
AU2018221730A1 (en) | 2017-02-15 | 2019-08-29 | 2Seventy Bio, Inc. | Donor repair templates multiplex genome editing |
CA3064014A1 (en) | 2017-05-25 | 2018-11-29 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
WO2019070974A1 (en) | 2017-10-04 | 2019-04-11 | Bluebird Bio, Inc. | PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE |
EP3696272A1 (en) | 2017-12-22 | 2020-08-19 | Oxford BioMedica (UK) Limited | Retroviral vector |
DE102018010282A1 (de) | 2018-01-17 | 2019-07-18 | Immatics US, Inc. | Verfahren zur Feststellung der Wirksamkeit von viralen Vektoren |
DE102018100967B4 (de) | 2018-01-17 | 2019-08-14 | Immatics US, Inc. | Verfahren zur feststellung der wirksamkeit von viralen vektoren |
KR20210021522A (ko) | 2018-06-14 | 2021-02-26 | 블루버드 바이오, 인코포레이티드. | Cd79a 키메라 항원 수용체 |
TW202019474A (zh) | 2018-07-11 | 2020-06-01 | 美商西建公司 | 抗bcma嵌合抗原受體之用途 |
SG11202102058UA (en) | 2018-08-30 | 2021-03-30 | Tenaya Therapeutics Inc | Cardiac cell reprogramming with myocardin and ascl1 |
WO2020072059A1 (en) | 2018-10-04 | 2020-04-09 | Bluebird Bio, Inc. | Cblb endonuclease variants, compositions, and methods of use |
US20230137971A1 (en) | 2019-07-11 | 2023-05-04 | Tenaya Therapeutics Inc. | Cardiac cell reprogramming with micrornas and other factors |
EP3770264A1 (en) | 2019-07-22 | 2021-01-27 | Genethon | Precise integration using nuclease targeted idlv |
EP4032907A4 (en) | 2019-09-20 | 2023-07-05 | Shanghai Genbase Biotechnology Co., Ltd. | BCMA-TARGETING CHEMERA ANTIGENIC ANTIBODIES AND RECEPTOR |
US20210128619A1 (en) | 2019-11-05 | 2021-05-06 | Celgene Corporation | Uses of anti-bcma chimeric antigen receptors |
KR20220097492A (ko) | 2019-11-12 | 2022-07-07 | 옥스포드 바이오메디카(유케이) 리미티드 | 생산 시스템 |
WO2021160993A1 (en) | 2020-02-13 | 2021-08-19 | Oxford Biomedica (Uk) Limited | Production of lentiviral vectors |
JP2023516493A (ja) | 2020-03-13 | 2023-04-19 | オックスフォード バイオメディカ(ユーケー)リミテッド | レンチウイルスベクター |
CN111534533B (zh) * | 2020-04-27 | 2022-04-19 | 北京化工大学 | 一种t7rna聚合酶和t7启动子的表达系统及使用其在真核生物中表达蛋白质的方法 |
GB202007199D0 (en) | 2020-05-15 | 2020-07-01 | Oxford Biomedica Ltd | Viral vector production |
US11781156B2 (en) | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
EP3984548A1 (en) | 2020-10-16 | 2022-04-20 | Institut Pasteur | Generation of lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses immune response in a host |
WO2022098685A2 (en) | 2020-11-04 | 2022-05-12 | Celgene Corporation | Car t cell therapy in patients who have had prior anti-cancer alkylator therapy |
GB202017725D0 (en) | 2020-11-10 | 2020-12-23 | Oxford Biomedica Ltd | Method |
US20240016936A1 (en) | 2020-12-04 | 2024-01-18 | Celgene Corporation | Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors |
CA3209285A1 (en) | 2021-03-12 | 2022-09-15 | Pierre Charneau | Lentiviral vectors targeting antigens to mhc-ii pathway and inducing protective cd8+ and cd4+ t-cell immunity in a host |
CA3214280A1 (en) | 2021-04-16 | 2022-10-20 | Julie Ann RYTLEWSKI | T cell therapy in patients who have had prior stem cell transplant |
CN117980326A (zh) | 2021-07-14 | 2024-05-03 | 2赛文缇生物公司 | 与来自抗体的结合结构域融合的经工程化的t细胞受体 |
GB202114528D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202114532D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral Vectors |
GB202114530D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Retroviral vectors |
GB202114529D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Lentiviral vectors |
GB202114534D0 (en) | 2021-10-12 | 2021-11-24 | Oxford Biomedica Ltd | Novel viral regulatory elements |
CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
GB202117844D0 (en) | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
US20230346977A1 (en) | 2022-04-13 | 2023-11-02 | Universitat Autònoma De Barcelona | Treatment of neuromuscular diseases via gene therapy that expresses klotho protein |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023230512A1 (en) | 2022-05-26 | 2023-11-30 | 2Seventy Bio, Inc. | Compositions for maintaining lentiviral vector and uses thereof |
GB202211935D0 (en) | 2022-08-16 | 2022-09-28 | Oxford Biomedica Ltd | envelope proteins |
WO2024084041A2 (en) | 2022-10-21 | 2024-04-25 | Institut Pasteur | Polynucleotides and lentiviral vectors expressing non-structural antigens of a flavivirus selected from the group of denv, zikv and yfv, inducing protective cd8+ t-cell immunity in a host |
WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3140757B2 (ja) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
EP0882134B8 (en) * | 1996-02-21 | 2009-09-02 | Genetic Immunity kft. | Methods and compositions for protective and therapeutic genetic immunization |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
AU3988799A (en) | 1998-05-13 | 1999-11-29 | Genetix Pharmaceuticals, Inc. | Novel lentiviral packaging cells |
EP1141314A2 (en) * | 1998-12-31 | 2001-10-10 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
WO2000072886A1 (en) * | 1999-05-26 | 2000-12-07 | Dana-Farber Cancer Institute, Inc. | Episomally replicating lentiviral vectors |
AU784910B2 (en) | 1999-10-12 | 2006-07-27 | Centre National De La Recherche Scientifique | Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
AU9307501A (en) * | 2000-09-22 | 2002-04-02 | Virxsys | Improved conditionally replicating vectors, methods for their production and use |
FR2825372B1 (fr) | 2001-06-01 | 2004-06-18 | Centre Nat Rech Scient | Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus |
US20070042494A1 (en) * | 2005-05-31 | 2007-02-22 | Tal Kafri | Heterologous retroviral packaging system |
-
2004
- 2004-06-25 FR FR0407017A patent/FR2872170B1/fr not_active Expired - Fee Related
-
2005
- 2005-06-24 EP EP05779704A patent/EP1761635B1/fr not_active Not-in-force
- 2005-06-24 JP JP2007517365A patent/JP4861314B2/ja not_active Expired - Fee Related
- 2005-06-24 CA CA2579753A patent/CA2579753C/fr not_active Expired - Fee Related
- 2005-06-24 US US11/628,534 patent/US8119119B2/en not_active Expired - Fee Related
- 2005-06-24 AU AU2005266221A patent/AU2005266221B2/en not_active Ceased
- 2005-06-24 CN CNA2005800209389A patent/CN101023177A/zh active Pending
- 2005-06-24 WO PCT/FR2005/001604 patent/WO2006010834A1/fr active Application Filing
- 2005-06-24 AT AT05779704T patent/ATE524554T1/de not_active IP Right Cessation
-
2006
- 2006-11-30 IL IL179740A patent/IL179740A0/en unknown
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017214938A1 (zh) * | 2016-06-16 | 2017-12-21 | 毛侃琅 | 特异促进 bace1 基因高表达的慢病毒表达载体及应用 |
WO2021212279A1 (zh) * | 2020-04-20 | 2021-10-28 | 广东东阳光药业有限公司 | 慢病毒的滴度提高型转移质粒 |
Also Published As
Publication number | Publication date |
---|---|
IL179740A0 (en) | 2007-05-15 |
FR2872170A1 (fr) | 2005-12-30 |
CA2579753A1 (fr) | 2006-02-02 |
EP1761635A1 (fr) | 2007-03-14 |
JP2008503230A (ja) | 2008-02-07 |
EP1761635B1 (fr) | 2011-09-14 |
FR2872170B1 (fr) | 2006-11-10 |
WO2006010834A1 (fr) | 2006-02-02 |
AU2005266221A1 (en) | 2006-02-02 |
AU2005266221B2 (en) | 2010-06-10 |
US8119119B2 (en) | 2012-02-21 |
CA2579753C (fr) | 2015-04-14 |
US20080089863A1 (en) | 2008-04-17 |
ATE524554T1 (de) | 2011-09-15 |
JP4861314B2 (ja) | 2012-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101023177A (zh) | 非-整合型以及非-复制型慢病毒,制剂及其应用 | |
DE60028066T2 (de) | Lentivirale vektoren für die herstellung von immunotherapeutischen zusammensetzungen | |
DE69631795T2 (de) | Vektor und verfahren zur einbringung von nukleinsäure in sich nicht teilende zellen | |
JP4571306B2 (ja) | ヌクレオチド配列の導入のためのトリプレックス構造のdna配列の利用 | |
DE60033045T2 (de) | Lentivirale triplex-dns, und vektoren und rekombinante zellen, die lentivirale triplex-dns enthalten | |
CH684094A5 (de) | Rekombinante Retroviren. | |
WO1997012622A9 (en) | Vector and method of use for nucleic acid delivery to non-dividing cells | |
EP1549756A2 (en) | Recombinatant mutants of rhabdovirus and methods of use thereof | |
US20220106385A1 (en) | Use of modified hiv-1 for generating fully human antibodies | |
CN101180082B (zh) | 利用siv-pedf载体治疗伴随眼组织细胞凋亡变性的疾患的药物 | |
CN104736167B (zh) | 含有mhc i型启动子的慢病毒载体 | |
CN101160139B (zh) | 含有pedf以及fgf2的伴随眼组织细胞凋亡变性的疾患的治疗药物 | |
DE69626681T2 (de) | Konditionell-replizierende virale vektoren und ihre verwendung. | |
EP1392838B1 (fr) | Pseudotypage de vecteurs hiv par des enveloppes de virus mokola | |
DE602004013165T2 (de) | Chimärisches vektorsystem | |
JP2001501815A (ja) | 非分裂細胞への形質導入が可能なレトロウイルスベクター | |
JP2006502240A5 (zh) | ||
AU758600B2 (en) | Vector and method of use for nucleic acid delivery to non-dividing cells | |
WO2004037846A1 (de) | Immunisierung gegen bestandteile des humanen immunschwächevirus (hiv) | |
AU2003271326A1 (en) | Use of triplex structure DNA sequences for transferring nucleotide sequences |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Philippe Stephanie Inventor after: Serguera Che Inventor after: Mallet Jacques Inventor after: Chamchi Sachs Inventor before: Philippe Stephanie Inventor before: Serguera Che Inventor before: Mallet Jacques |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: MALLET JACQUES SERGUERA CHE PHILIPPE STEPHANIE TO: MALLET JACQUES SERGUERACHE PHILIPPE STEPHANIE SARQUISS CHARMS |
|
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20070822 |
|
C20 | Patent right or utility model deemed to be abandoned or is abandoned |